The company joins a group of degrader ADC (or DAC) developers that includes Bristol Myers Squibb and Pfizer.

A Roche drug that is one of the company’s top cancer products is expanding to autoimmune disease with a new FDA approval in lupus nephritis. The intravenously infused drug, Gazyva, may now be used to ...

Childhood cancer treatments can accelerate biological aging, increasing risks for long-term health issues like heart disease and hypertension. Epigenetic age acceleration measures the difference ...

Aviva Bio is advancing AVA-291 (d3-T) as a differentiated testosterone in a broad development program addressing multiple ...

New data from a phase 1b/2 clinical trial shows that a specific protein called CD47 can help predict how well the investigational drug evorpacept works for patients with metastatic breast cancer, ALX ...

The Preston Robert Tisch Brain Tumor Center grants first IRB approval for APTN-101’s Phase I clinical trial, enabling patient recruitment to ...

Pancreatic ductal adenocarcinoma is one of the deadliest cancers due to its late detection, dense tumour structure, and ...

Researchers in Sweden have identified an unexpected biological mechanism that could influence future cancer treatments. Scientists in Sweden have uncovered an unexpected anti-cancer effect from a ...

Advanced imaging, particularly PSMA PET scans, enhances detection of microscopic disease, allowing for more precise treatment ...

Researchers developed FaceAge, an AI tool that calculate's a patient biological age from a photo of their face. In a new study, the researchers tied FaceAge results to health outcomes in people with ...

YD Bio Limited (“YD Bio Ltd” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced it ...